According to the National Institute of Health, Parkinson's disease affects 1 to 2 people per 1000 individuals. The prevalence increases with age and affects 1% of the population aged 60 years and above. The condition is more common in males as compared to females. Major pharma companies and research institutes are developing and bringing new therapies, thereby, accelerating the drug pipeline significantly.
The Parkinson’s Disease Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into xx therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for Parkinson’s disease. The Parkinson’s disease report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The Parkinson’s disease pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from the condition, and alignment with Parkinson’s disease treatment guidelines to ensure optimal care practices.
The detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration and ongoing Parkinson’s disease pipeline development activities are covered. Moreover, Parkinson’s disease collaborations and commercial assessments are offered, helping stakeholders to make informed decisions.
Parkinson's disease is a progressive disorder which affects the nervous system and other parts of the body controlled by the nerves. The disorder causes stiffness or slowed movement. The average age at which this condition starts is 60 years old and the condition progresses with age. The disease is very common and ranks as the second most common age-related degenerative brain disease. It is also the most common movement-related brain disease.
The symptoms of Parkinson’s disease vary for every individual and may include tremors, slowed movement (known as bradykinesia), impaired posture and balance, rigid muscles, loss of automatic movements and speech changes among others. The treatment for Parkinson’s disease includes medications and surgical procedures. The medications include carbidopa-levodopa, inhaled carbidopa-levodopa, carbidopa-levodopa infusion, dopamine agonists, monoamine oxidase B (MAO B) inhibitors, catechol O-methyltransferase (COMT) inhibitors, anticholinergics, amantadine, and adenosine receptor antagonists among others.
There are several unmet needs for patients. For instance, there is not an efficient treatment for motor symptoms such as levodopa-induced dyskinesia and imbalance. However, novel therapies which are currently in phase II and III trials are developing innovative treatments including the treatment of motor symptoms and are expected to revolutionize treatment for patients. Annovis Bio is currently in a phase III trial which is evaluating the efficacy, safety, and tolerability of DMT buntanetap tartrate. The mechanism of the drug involves inhibiting the production of neurotoxic proteins derived from the amyloid precursor protein (APP). The presence of large clinical trials for Parkinson’s disease is influencing the pipeline landscape significantly.
This section of the report covers the analysis of Parkinson’s disease drug candidates based on several segmentations including:
By Phase
EMR’s pipeline assessment report covers 50+ drug analyses based on phase.
By Drug Class
EMR’s Parkinson’s disease therapeutics assessment report covers 50+ drug analyses based on drug classes:
By Route of Administration
EMR’s pipeline assessment report covers 50+ drug analyses based on the route of administration.
The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total clinical trials for Parkinson’s disease with 572 pipeline drugs in the respective phase.
The drug molecules categories covered under Parkinson’s disease pipeline analysis include small molecule, monoclonal antibody, and peptide. Prasinezumab is a monoclonal antibody which binds aggregated α-synuclein and is being investigated as a potential disease-modifying therapy for the treatment of early-stage Parkinson’s disease. The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for Parkinson’s disease.
The EMR Parkinson’s disease drug report insights involve the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in Parkinson’s disease clinical trials:
This section covers the detailed analysis of each drug under multiple phases including phase I, phase II, phase III, phase IV, and emerging drugs for Parkinson’s disease. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of Parkinson’s disease drug candidates.
The trial is designed to evaluate the tolerability and efficacy of spheramine in patients with advanced Parkinson’s disease. The trial is sponsored by Bayer and is currently under phase II.
The objective of the study is to evaluate the clinical safety and effectiveness of IPu-infused liatermin (15mg/putamen/day) in patients with symptomatic, levodopa-response Parkinson’s disease. The trial is sponsored by Amgen and is currently under phase I.
UCB Pharma is developing the drug, and it is currently under phase III. The study is designed to demonstrate that Rotigotine transdermal patch is effective with advanced-stage idiopathic Parkinson’s disease as an adjuvant therapy.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Parkinson’s Disease Drug Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for Parkinson’s disease. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into Parkinson’s disease collaborations, regulatory environments, and potential growth opportunities within the treatment landscape.
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| Scope of the Report | Details |
| Drug Pipeline by Clinical Trial Phase |
|
| Route of Administration |
|
| Drug Classes |
|
| Leading Sponsors Covered |
|
| Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share